Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 7/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.41 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.41 |
| ▸ | TERT | O14746 | 3/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19944721 | 0.99 | ERAP2 (0.42) | ERAP2LNPEPERAP1SUV39H2TERT | |
| SCHEMBL19219138 | 0.98 | ERAP2 (0.42) | ERAP2LNPEPERAP1SUV39H2TERT | |
| SCHEMBL19945129 | 0.98 | ERAP2 (0.42) | ERAP2LNPEPERAP1SUV39H2TERT | |
| SCHEMBL10199276 | 0.97 | ERAP2 (0.42) | ERAP2LNPEPERAP1SUV39H2TERT | |
| SCHEMBL10199359 | 0.97 | ERAP2 (0.42) | ERAP2LNPEPERAP1SUV39H2TERT | |
| SCHEMBL10199175 | 0.97 | ERAP2 (0.42) | ERAP2LNPEPERAP1SUV39H2TERT | |
| SCHEMBL10199372 | 0.97 | ERAP2 (0.42) | ERAP2LNPEPERAP1SUV39H2TERT | |
| SCHEMBL10261754 | 0.94 | ERAP2 (0.46) | ERAP2LNPEPERAP1SUV39H2TERT | |
| SCHEMBL19945106 | 0.94 | ERAP2 (0.41) | ERAP2LNPEPERAP1SUV39H2TERT | |
| SCHEMBL10262189 | 0.93 | AAK1 (0.40) | AAK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10206894-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206894-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, SI | ERAP2 692/4885LNPEP 802/4885ERAP1 1246/4885 |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | MUC1, FUT6, SI | ERAP2 692/4885LNPEP 802/4885ERAP1 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.